Membership is open to all organizations and individuals who are committed to zero leprosy and that support the principles, objectives, and activities of the Global Partnership for Zero Leprosy. Learn more.
Since the introduction of effective multi-drug therapy (MDT) 30 years ago, the reported prevalence of leprosy has been reduced by 99%. However, the number of newly diagnosed leprosy patients has remained above 200,000 per year for the last decade, including thousands of children.
New scientific advances are changing the way we approach leprosy and may provide innovative ways to fully interrupt transmission of the disease. Recent scientific breakthroughs include improved diagnostic methods, more effective ways to prevent the spread of infections, and new ways of treating people at greatest risk.
Along with these innovations, achieving zero leprosy requires a strong global alignment behind a common vision. The leprosy community feels a renewed sense of urgency to accelerate progress through collaboration. The Global Partnership for Zero Leprosy will build on and strengthen existing collaborative networks to support leprosy programs as they adopt new tools and approaches.
View our upcoming and long-term milestones towards zero leprosy. Learn more.
Advice about leprosy and COVID-19 from the WHO Global Leprosy Programme, ILEP, and GPZL. Includes guidance on diagnosis and clinical management of leprosy patients, public health aspects of leprosy in the COVID-19 pandemic, and services for persons living with disabilities and/or psychosocial consequences of leprosy.